Lactic acid bacteria strain food composition and pharmaceutical composition for treating gastric ulcer

A pharmaceutical composition and the technology of the composition are applied in the field of food compositions and pharmaceutical compositions, and can solve the problems of side effects, affecting the compliance of patients taking medicine, etc.

Active Publication Date: 2012-12-26
锦乔生物科技有限公司
View PDF1 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But this three-in-one therapy also has its disadvantages, including the generation of side effects, such as nausea, diarrhea, flatulence, dizziness, etc., which often affect the patient's compliance with medication.
[0005] Generally, eating products containing lactic acid bacte

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactic acid bacteria strain food composition and pharmaceutical composition for treating gastric ulcer
  • Lactic acid bacteria strain food composition and pharmaceutical composition for treating gastric ulcer
  • Lactic acid bacteria strain food composition and pharmaceutical composition for treating gastric ulcer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: Morphological and general properties of gastric Helicobacter pylori resistant lactic acid bacteria.

[0022] According to the 16S rDNA sequence analysis and the API bacterial identification system analysis results, the taxonomic characteristics of the strains were confirmed. It is found that the two strains of lactic acid bacteria described in the present invention are Lactobacillus salivarius and Lactobacillus johnsonii respectively. The characteristics of the above strains in morphology and general properties are listed in Table 2:

[0023] Table 2

[0024]

Embodiment 2

[0025] Embodiment 2: The effect of the lactic acid bacteria of anti-gastric Helicobacter pylori on inhibiting the activity of gastric Helicobacter pylori decomposing urea to produce ammonia and carbon dioxide is mainly to detect the concentration of ammonia and inhibit the percentage of gastric Helicobacter pylori (with the urease activity of liquid culture The analytical test is an in vitro efficacy verification platform).

[0026] Detect the urease inhibitory effect of the lactic acid bacteria strains of the anti-gastric Helicobacter pylori-Lactobacillus salivarius AP-32 strain CCTCC NO: M 2011127 and Lactobacillus johnsonii MH-68 strain CCTCC NO: M 2011128 of the present invention, which is the gastric Helicobacter pylori was co-cultured with the above-mentioned anti-gastric Helicobacter pylori lactic acid bacteria respectively, and then the concentration of ammonia in the culture medium was measured to verify the anti-gastric Helicobacter pylori ability of the above strains...

Embodiment 3

[0041] Example 3: Preliminary test of lactic acid bacteria in house human clinical trial against gastric Helicobacter pylori.

[0042] Gastric Helicobacter pylori secretes urease, which decomposes urea to produce ammonia and carbon dioxide. therefore, 13 The C breath test was developed using this feature, the principle of this method is that the gastric Helicobacter pylori produces urease in the body and uses 13 C or 14 After the C-labeled urea is taken by the subject, it will decompose to produce isotope-labeled carbon dioxide, collect breath samples, and use a liquid scintillation counter or a gas nuclear mass spectrometer to detect the labeled carbon dioxide, which has high sensitivity and can be quantified. The patient is painless, the method is simple and fast, and it is very reliable for detecting whether gastric Helicobacter pylori has been eradicated. But because 14 C has a small amount of radioactive substances, so it is currently used 13 C urea breath test metho...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a food composition and a pharmaceutical composition, and in particular relates to a lactic acid bacteria strain food composition and pharmaceutical composition for treating gastric ulcer.

Description

technical field [0001] The invention relates to a food composition and a medical composition, in particular to a food composition and a medical composition of lactic acid bacteria strains for treating gastric ulcer. Background technique [0002] Gastric Helicobacter pylori was discovered by Marshall and Warren in 1982 to be associated with ulcerative inflammation of the digestive organs. Ulcerative inflammation of the digestive organs has long been thought to be caused by excessive secretion of gastric juice due to stress and lifestyle, causing ulcerative inflammation to recur. Therefore, the treatment of this disease has been aimed at inhibiting the secretion of gastric juice or neutralizing the acidity of gastric juice, so that the disease can be alleviated. It was not until the existence of gastric Helicobacter pylori was discovered in 1982 that the development of antibiotic treatment began, which shortened the time course of treatment for peptic ulcer disease. In 2005,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A23L1/30A61K35/74A61P1/04A61K35/744A61K35/747
Inventor 谢佩珊蔡宜钧郭仲伟陈怡君
Owner 锦乔生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap